Compare Novavax Inc (NVAX) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs QUALCOMM, Inc. — how do they compare? Novavax Inc trades at $7.96 (market cap $1.30B), while QUALCOMM, Inc. trades at $163.97 (market cap $170.28B). The key difference: QUALCOMM, Inc. is far larger — about 131× Novavax Inc's market cap, and QUALCOMM, Inc. pays a 2.27% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | QCOM | |
|---|---|---|
Market Cap | $1.30B | $170.28B |
Sector | Health | Technology |
52-Week High | $11.19 | $251.10 |
52-Week Low | $6.22 | $124.07 |
Enterprise Value | $879.40M | $177.24B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Qualcomm (QCOM) trades at $162.68, down 3.09% amid broader semiconductor sector pressure. The stock shows mixed signals with bearish technical indicators but strong fundamentals including recent earnings beats and a 21.01% net income margin. Recent news highlights Qualcomm's strategic pivot toward AI and data centers, though competition from Nvidia's new PC chip has sparked investor concerns. The company maintains solid cash flow generation of $14.01B from operations in 2025 and continues dividend payments.
Qualcomm presents a compelling value opportunity with a P/E of 18.53 below sector averages, supported by analyst consensus price target of $200.56 implying 23% upside. Key risks include smartphone market softness and intensifying AI competition. The company's diversification into automotive and data centers provides growth catalysts, though execution risks remain. Current levels offer attractive entry for long-term investors seeking exposure to semiconductor and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
